🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Toward a Computationally-Informed, Personalized Treatment for Hallucinations

RecruitingEARLY Phase 1Ages 18 Years - 65 YearsAllYale University
NCT04366518 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Auditory hallucinations are among the most distressing aspects of psychotic illness, and between 10 and 30% of people with hallucinations do not respond to antipsychotic medications. The authors have used computational modeling of behavior to link brain activity to development of auditory hallucinations in the hope of guiding new treatment development. The proposed studies take the first step toward individualized treatment approaches to hallucinations by attempting causal, pharmacological manipulation of relevant model parameters underlying these phenomena.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Age 18-65 * English speaking * Right handedness * Diagnosed with schizophrenia schizoaffective, schizophreniform, schizotypal, or brief psychotic disorder * History of auditory verbal hallucinations occurring at least weekly Exclusion Criteria: * Current substance dependence or active use as determined by drug test. * Any neurological, medical or developmental problem that is known to impair cognition significantly * Contraindications for MR scanning including metallic implants of any kind, pacemakers and history of accidents with metal, claustrophobia * History of seizures * History of violence * History of suicide * Pregnancy (determined by urine pregnancy test) * Concurrent participation in any other intervention study * History of urinary retention * History of delirium * Current use of any cholinergic or anticholinergic medication * History of asthma, diabetes, and cardiovascular disease * Evidence of cardiovascular disease on EKG * Individuals who have been on dopamine-2 antagonists for less than 6 months (to limit risk of EPS)
💊

What it tests

  • Rivastigmine Transdermal System
  • Scopolamine
  • Placebo Patch
  • Placebo Patch
📍

Where

1 site
Connecticut Mental Health Center
New Haven, United States
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy